Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 4/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058366 | 0.82 | RXFP1 (0.47) | MAOBBRD4MAPTMAPK1TDP1 | |
| SCHEMBL2454830 | 0.76 | ALDH1A1 (0.50) | MAOBBRD4MAPTTDP1KDM4E | |
| SCHEMBL21379597 | 0.71 | HSD17B3 (0.46) | MAOBBRD4MAPTKDM4EALDH1A1 | |
| SCHEMBL10655601 | 0.71 | MAOB (0.58) | MAOBBRD4ACHEMAOAEDNRA | |
| SCHEMBL17704705 | 0.69 | MAOB (0.69) | MAOBACHEMAOAEDNRAKDM4E | |
| SCHEMBL1147722 | 0.68 | HSD17B3 (0.51) | MAOAMAPTMAPK1KDM4EALDH1A1 | |
| SCHEMBL3063473 | 0.68 | HSD17B3 (0.44) | MAOBBRD4MAPTMAPK1KDM4E | |
| SCHEMBL26095806 | 0.68 | MAPT (0.49) | MAOBL3MBTL1MAPTMAPK1TDP1 | |
| SCHEMBL4218836 | 0.68 | MAOB (0.54) | MAOBACHEMAOAKDM4EALDH1A1 | |
| SCHEMBL26360003 | 0.67 | L3MBTL1 (0.56) | BRD4L3MBTL1MAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-12-20 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1248614-A4 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | UNIV CALIFORNIA (US) | 2005-05-04 | — | — | EP | disclosed |
| US-6803375-B1 | IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | disclosed |
| EP-1248614-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | The Regents of The University of California (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001049663-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | NFATC1, ORAI1, KCNMA1 | MAOB 3426/4885BRD4 3230/4885ACHE 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.